Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07544862 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Jun 2026 to Jun 2, 2026
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Trial Details
NCT Number NCT07544862
Lead Sponsor Chengdu Kangnuoxing Biopharma,Inc.
Conditions
(from sponsor)		 Atopic Dermatitis (AD)
Related terms Dermatitis, Atopic
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov